Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Depression and neurocognitive performance in Portuguese patients infected with HIV.

Bragança M, Palha A.

AIDS Behav. 2011 Nov;15(8):1879-87. doi: 10.1007/s10461-011-9973-3.

PMID:
21598031
2.

Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up.

Gibbie T, Mijch A, Ellen S, Hoy J, Hutchison C, Wright E, Chua P, Judd F.

HIV Med. 2006 Mar;7(2):112-21.

3.

Depressive symptoms and neurocognitive performance among HIV-infected women.

Fialho RM, Pereira M, Mendonça N, Ouakinin S.

Women Health. 2013;53(2):117-34. doi: 10.1080/03630242.2013.767301.

PMID:
23517511
4.

Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women.

Cohen RA, Boland R, Paul R, Tashima KT, Schoenbaum EE, Celentano DD, Schuman P, Smith DK, Carpenter CC.

AIDS. 2001 Feb 16;15(3):341-5.

PMID:
11273214
5.

Medication adherence in HIV-infected smokers: the mediating role of depressive symptoms.

Webb MS, Vanable PA, Carey MP, Blair DC.

AIDS Educ Prev. 2009 Jun;21(3 Suppl):94-105. doi: 10.1521/aeap.2009.21.3_supp.94.

PMID:
19537957
6.

Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.

Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau FM, De Felici A, Benedetto A.

AIDS. 1999 Oct 1;13(14):1889-97.

PMID:
10513647
7.

Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning.

Millikin CP, Rourke SB, Halman MH, Power C.

J Clin Exp Neuropsychol. 2003 Apr;25(2):201-15.

PMID:
12754678
8.

Characterization of HIV-Associated Neurocognitive Disorders among individuals starting antiretroviral therapy in South Africa.

Joska JA, Westgarth-Taylor J, Myer L, Hoare J, Thomas KG, Combrinck M, Paul RH, Stein DJ, Flisher AJ.

AIDS Behav. 2011 Aug;15(6):1197-203. doi: 10.1007/s10461-010-9744-6.

PMID:
20614176
9.

The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.

Jevtović Dj, Vanovac V, Veselinović M, Salemović D, Ranin J, Stefanova E.

Biomed Pharmacother. 2009 Sep;63(8):561-5. doi: 10.1016/j.biopha.2008.09.015. Epub 2008 Nov 5.

PMID:
19026516
10.

Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings.

Cherner M, Ellis RJ, Lazzaretto D, Young C, Mindt MR, Atkinson JH, Grant I, Heaton RK; HIV Neurobehavioral Research Center Group.

AIDS. 2004 Jan 1;18 Suppl 1:S27-34.

PMID:
15075495
11.

Impact of social support on cognitive symptom burden in HIV/AIDS.

Atkins JH, Rubenstein SL, Sota TL, Rueda S, Fenta H, Bacon J, Rourke SB.

AIDS Care. 2010 Jul;22(7):793-802. doi: 10.1080/09540120903482994.

PMID:
20635243
12.

Neuropsychological functioning in a cohort of HIV infected women: importance of antiretroviral therapy.

Richardson JL, Martin EM, Jimenez N, Danley K, Cohen M, Carson VL, Sinclair B, Racenstein JM, Reed RA, Levine AM.

J Int Neuropsychol Soc. 2002 Sep;8(6):781-93. Erratum in: J Int Neuropsychol Soc. 2005 Jan;11(1):120.

PMID:
12240742
13.

Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function.

Ferrando S, van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J.

AIDS. 1998 May 28;12(8):F65-70.

PMID:
9631133
14.

Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning.

Rourke SB, Halman MH, Bassel C.

J Clin Exp Neuropsychol. 1999 Dec;21(6):737-56.

PMID:
10649531
15.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group.

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
16.

The impact of HIV-associated neuropsychological impairment on everyday functioning.

Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I; HNRC Group.

J Int Neuropsychol Soc. 2004 May;10(3):317-31.

PMID:
15147590
17.

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.

Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63. Erratum in: J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):529.

PMID:
19731418
18.

Neuropsychological impairment-associated visual field deficits in HIV infection. HNRC Group. HIV Neurobehavioral Research Center.

Plummer DJ, Marcotte TD, Sample PA, Wolfson T, Heaton RK, Grant I, Freeman WR.

Invest Ophthalmol Vis Sci. 1999 Feb;40(2):435-42.

PMID:
9950603
19.

Use of highly active antiretroviral therapy in HIV-infected women: impact of HIV specialist care.

Gardner LI, Holmberg SD, Moore J, Arnsten JH, Mayer KH, Rompalo A, Schuman P, Smith DK; HIV Epidemiology Research Study Group.

J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):69-75.

PMID:
11782593
20.

Sociodemographic and psychological variables influencing adherence to antiretroviral therapy.

Gordillo V, del Amo J, Soriano V, González-Lahoz J.

AIDS. 1999 Sep 10;13(13):1763-9.

PMID:
10509579

Supplemental Content

Support Center